New hope for reversing early-stage ms?
MS has been the graveyard of forlorn hopes, as I learned while my friend Nadine struggled gallantly with the disease. But research at Cambridge University may offer hope for early-stage ms patients.
A study published in the New England Journal of Medicine suggests that a new drug may stop the disease in its tracks and reverse its progress in early-phase patients.
Alemtuzumab, "is more effective than beta interferon by a country mile", said Alistair Compston, Professor of Neurology at the University of Cambridge, who led the study. "The efficacy is so high that we hope it will represent the definitive treatment if used in the right people.”
Serious side-effects were observed in a few patients.
Hope, hopefully not forlorn.
A separate Canadian study appears to support the idea that low levels of Vitamin D in children might be correlated to high incidences of the disease.